I

I.1 AUTHORIZATION FOR TESTING

To:	___________________

Player	___________________

Please be advised that on __________________________, you were the subject of a meeting or conference call held pursuant to the Anti-Drug Program set forth in Article XXXIII of the Collective Bargaining Agreement between the NBA and the National Basketball Players Association, dated January 19, 2017, (the “Agreement”). Following the meeting or conference call, I authorized the NBA to conduct the testing procedures set forth in the Agreement, and you are hereby directed to submit to those testing procedures, on demand, no more than four (4) times during the next six (6) weeks.

Please be advised that your failure to submit to these procedures may result in substantial penalties, including but not limited to your dismissal and disqualification from the NBA.

________________________

Independent Expert

Dated:

________________________

I.2 PROHIBITED SUBSTANCES

A. Drugs of Abuse

Benzodiazepines:
- Alprazolam (also called Xanax or Niravam)
- Chlordiazepoxide (also called Librium, Mitran, Poxi or H-Tran)
- Clonazepam (also called Klonopin, Ceberclon or Valpaz)
- Diazepam (also called Valium)
- Lorazepam (also called Ativan)
Synthetic Cathinones
- 4-methyl-N-ethylcathinone (also called 4-MEC)
- 4-methyl-alpha-pyrrolidinopropiophenone (also called 4-MePPP)
- Alpha-pyrrolidinopentiophenone (also called alpha-PVP)
- 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (also called butylone)
- 2-(methylamino)-1-phenylpentan-1-one (also called pentedrone)
- 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (also called pentylone)
- 4-fluoro-N-methylcathinone (also called 4-FMC)
- 3-fluoro-N-methylcathinone (also called 3-FMC)
- 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (also called naphyrone)
- alpha-pyrrolidinobutiophenone (also called alpha-PBP)
Cocaine
Gamma Hydroxybutyrate (GHB)
Ketamine
LSD
Methamphetamine, MDMA, MDA and MDEA
Opiates:
- Heroin
- Codeine
- Morphine
- Oxycodone (also called Oxycontin, Percocet, Percodan, Roxicet, Tylox, Dazidox, Endocet or Endodan)
- Hydrocodone (also called Vicodin, Lorcet, Lortab, Hydocan or Norco)
- Methadone (also called Methadose or Dolophine)
- Hydromorphone (also called Dilaudid)
- Fentanyl (also called Actiq or Duragesic)
- Propoxyphene (also called Darvon or Darvocet)
- Phencyclidine (PCP)

B. Marijuana Marijuana and its By-Products

Synthetic Cannabinoids:
- 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (also called CP-47,497)
- 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (also called cannabicyclohexanol or CP-47,497 C8-homolog)
- 1-pentyl-3-(1-naphthoyl)indole (also called JWH-018 or AM678)
- 1-butyl-3-(1-naphthoyl)indole (also called JWH-073)
- 1-hexyl-3-(1-naphthoyl)indole (also called JWH-019)
- 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200)
- 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250)
- 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081)
- 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122)
- 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398)
- 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (also called AM2201)
- 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (also called AM694)
- 1-pentyl-3-[(4-methoxy)-benzoyl]indole (also called SR-19 or RCS-4)
- 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (also called SR-18 or RCS-8)
- 1-pentyl-3-(2-chlorophenylacetyl)indole (also called JWH-203)

C. Steroids and Performance Enhancing Drugs (SPEDs)

Adrafinil
Alexamorelin
Aminoglutethimide
Amiphenazole
Amphetamine and its analogs (with the exceptions of Methamphetamine, MDMA, MDA and MDEA)
Anamorelin
Anastrozole
Androsta-1,4,6-triene-3,17-dione (also called Androstatrienedione or ATD)
Androsta-3, 5-diene-7, 17-dione (also called Arimistane)
Androst-2-en-17-one (also called 2-Androstenone and Delta-2)
Androstanediol
Androstanedione
Androstenediol
Androstenedione
Androstene-3,6,17-trione (also called 6-OXO or 4-AT)
Bolasterone
Boldenone
Boldione
Bromantan
- 6-bromo-androstan-3,17-dione (also called 6-Bromo)
- 6-bromo-androsta-1,4-diene,3,17-dione (also called Aromadrol)
Calusterone
- 4-chloro-17a-methyl-androsta-1,4-diene-3,17b-diol (also called Halodrol, Halovar and Helladrol)
- 4-chloro-17a-methyl-androst-4-ene-3b,17b-diol (also called P-Mag and Promagnon)
- 4-chloro-17a-methyl-17b-hydroxyandrost-4-ene-3-one (also called Mechabol)
- 4-chloro-17a-methyl-17b-hydroxyandrost-4-ene-3,11-dione (also called Oxyguno)
Clenbuterol
Clobenzorex
Clomiphene
Clostebol
Cyclofenil
Danazol
Dehydrochloromethyltestosterone (also called DHCMT and Turinabol)
Dehydroepiandrosterone (DHEA)
Desoxymethyltestosterone (DMT)
Dihydrotestosterone
- 4-dihydrotestosterone
- 1, 3-dimethylamylamine (also called DMAA, Methylhexaneamine and Dimethylpentylamine)
- 2a,17a-dimethyl-17b-hydroxy-5bandrostan-3-one (also called Superdrol)
Dromostanolone
Drostanolone
Ephedra (also called Ma Huang Bishop’s Tea and Chi Powder)
Ephedrine
Epitestosterone
- 2a,3a-epithio-17a-methyl-5aandrostan-17b-ol (also called Epistane and Havoc)
Erythropoietin (EPO)
Estra-4,9,11-triene, 17-dione (also called Tren, Trenavar, Trendione and Trenazone)
- 13a-ethyl-17a-hydroxygon-4-en-3-one
Ethylestrenol
Etilefrine
Exemestane
Fencamfamin
Fenethylline
Fenfluramine
Fenproporex
Fluoxymesterone
Formebolone
Formestane (also called 4-hydroxyandrostenedione)
Fulvestrant
Furazabol
- [3,2-c]-furazan-5a-androstan-17b-ol (also called Furazan or Furuza)
Gestrinone
Ghrelin
Growth Hormone Releasing Peptide (GHRP)-1
- GHRP-2 (also called Pralmorelin)
- GHRP-4
- GHRP-5
- GHRP-6
Hexarelin
- 18a-homo-17b-hydroxyestr-4-en-3-one
- 18a-homo-3-hydroxy-estra-2,5(10)-dien-17-one (also called M-LMG)
Human Chorionic Gonadotropin
Human Growth Hormone (HGH)
- 3b-hydroxy-5a-androst-1-en-17-one (also called 1-Androsterone, 1-Andro and 1-DHEA)
- 17b-hydroxy-androstano[2,3-d]isoxazole (also called Androisoxazole)
- 17b-hydroxy-androstano[3,2-c]isoxazole
- 3b-hydroxy-estra-4,9,11-trien-17-one
- 4-hydroxytestosterone
Ibutamoren
Insulin-like Growth Factor (IGF-1)
Ipamorelin
Letrozole
Luteinizing Hormone (LH)
Mefenorex
Meldonium
Mestanolone
Mesterolone
Methandienone (also called Methandrostenolone)
Methandriol
Methasterone
Methenolone (also called Metenolone)
Methyldienolone
- 17a-methyl-androsta-1,4-diene-3,17bdiol (also called M1 and 4ADD)
- 17a-methyl-androst-2-ene-3,17b-diol
- 6a-methyl-androst-4-ene-3,17-dione
- 17a-methyl-androstan-3-hydroxyimine-17b-ol (also called D-Plex)
- 17a-methyl-5a-androstan-17b-ol (also called Methylandrostanol and Protobol)
- 17a-methyl-3a,17b-dihydroxy-5aandrostane
- 17a-methyl-3b,17bdihydroxy-5a-androstane
- 17a-methyl-3b,17b-dihydroxyandrost-4-ene
- 17a-methyl-1-dihydrotestosterone
- 17a-methyl-4-hydroxynandrolone
Methylephedrine
Methylphenidate
Methyltestosterone
Methyltrienolone (also called Metribolone)
Mibolerone
Modafinil
Nandrolone (also called 19-nortestosterone)
Nikethamide
- 19-norandrostenediol (also called Boldandiol)
- 19-norandrostenedione
Norbolethone (also called Norboletone)
Norclostebol
Norethandrolone
Norfenfluramine
Normethandrolone (also called Methylnortestosterone or MENT)
Norpseudoephedrine (also called Cathine)
Oxabolone (also called 4-hydroxy-19-nortestosterone)
Oxandrolone
Oxymesterone
Oxymetholone
Pemoline
Pentetrazol
Phendimetrazine
Phenmetrazine
Phentermine
Phenylpropanolamine (PPA)
Probenecid
Prostanozol
Pseudoephedrine
- [3,2,c]pyrazole-androst-4-en-17b-ol
Raloxifene
Quinbolone
Selective Androgen Receptor Modulator (SARM) S-1
- SARM S-4 (also called Andarine)
- SARM S-9
- SARM S-22 (also called Ostarine)
- SARM S-23
- SARM S-24
- SARM BMS-564,929
- SARM LGD-2226
- SARM LGD-4033 (also called Ligandrol)
Sermorelin
Stanozolol
Stenbolone
Strychnine
Tamoxifen
Tesamorelin
Testolactone
Testosterone
Tetrahydrogestrinone (THG)
Tibolone
Toremifene
Trenbolone
Zeranol
Zilpaterol

D. Diuretics

Acetazolamide
Amiloride
Bendroflumethiazide
Benzthiazide
Bumetanide
Canrenone
Chlorothiazide
Chlorthalidone
Clopamide
Cyclothiazide
Dichlorphenamide
Ethacrynic Acid
Flumethiazide
Furosemide
Hydrochlorothiazide
Hydroflumethiazide
Indapamide
Methyclothiazide
Metolazone
Polythiazide
Quinethazone
Spironolactone
Triamterene
Trichlormethiazide

I.3 URINE COLLECTION PROCEDURES

During the Season, collections for random testing will be scheduled to occur before practices on non-game days, and before shoot-arounds and games on game days. For random drug testing of a visiting team scheduled at game-day shoot-arounds, tests will be scheduled to occur before the shoot-around for that team commences, and for any tests that are not completed by the time the visiting team bus is scheduled to leave the arena or practice facility after the shoot-around is completed, the team will provide alternate transportation to the team hotel for any player that must remain at the arena or practice facility to complete the testing process and will ensure that a Team staff member remains with the affected player(s) and accompanies him or them back to the Team’s hotel. Random drug tests can be scheduled to occur at any time during the Off-Season.

When the player arrives at the collection site, the collector will ensure that the player is positively identified through presentation of photo ID or identification by a team representative. If the player’s identity cannot be established, the collector shall not proceed with the collection.

The player will be asked to select a sealed urine specimen cup. The player will then provide his urine specimen under the direct observation of the collector.

The collector shall ensure that the player has provided a urine specimen of sufficient volume for accurate testing. If such a sample cannot immediately be provided by the player, he shall be instructed to remain at the testing site for a reasonable period of time until he can provide such a specimen. Once the specimen has been obtained, the player will select a sealed specimen kit, which contains two bottles. The collector, in the presence of the player, will pour the specimen into two bottles. One bottle will be used as the primary or “A” specimen and the other will be used as the split or “B” specimen. The specimen bottles will be sealed with tamper-proof seals in the presence of the player. The seals will contain a unique identification number that corresponds to the number on the chain of custody form.

The player and collector will complete the chain of custody form (which may be in hard copy or electronic form) that documents the handling of the specimen. The collector will note any irregularities concerning the specimen on the chain of custody form. Both the player and collector will sign the chain of custody form. The kit will be sealed and sent via an overnight delivery service to the laboratory for testing. If a hard copy chain-of-custody form is used, it will be included in the kit containing the two specimens that is sent by overnight delivery service to the laboratory. If an electronic chain-of-custody form is used, it will be sent to the laboratory electronically.

Once the specimens arrive at the laboratory, the primary specimen will be analyzed. If the primary specimen tests positive, the split sample will be placed in frozen storage and will be available for testing by a different laboratory, if requested by the player.

I.4 BLOOD COLLECTION PROCEDURES

During the Season, collections for random testing will be scheduled to occur after practices on non-game days, and after games on game day. Random tests can be scheduled to occur at any time during the Off-Season.

The player will be asked to select two blood collection kits (one as a back-up) and another kit which will be used to transport the specimen. Collections will be performed by blood collection specialists (who are phlebotomists, registered and licensed nurses, medical assistants or paramedics).

The blood collection specialist shall collect a total of 10 ml of blood (approximately 1 tablespoon). The player’s non-dominant arm will be used to make the initial blood draw attempt. If the blood draw is not possible or successful from the non-dominant arm, the dominant arm may be used. No more than three (3) attempts will be made to draw a blood specimen. After that, the collection will be discontinued. Upon completing the blood draw, the blood collection specialist will ensure that the draw site is not bleeding and bandage the site.

The player and collector will complete the chain of custody form (which may be in hard copy or electronic form) that documents the handling of the specimens. Both the player and collector will sign the chain of custody form. The two specimens will be sealed in a blood specimen bag, and sent via an overnight delivery service to the laboratory for testing. If a hard copy chain-of-custody form is used, it will be included in the kit containing the two specimens that is sent by overnight delivery service to the laboratory. If an electronic chain-of-custody form is used, it will be sent to the laboratory electronically.

I.5 DRUGS OF ABUSE AND MARIJUANA CONFIRMATORY LABORATORY ANALYSIS LEVELS

Drugs of Abuse

Benzodiazepines 100 ng/ml
Synthetic Cathinones Any detectable level
Cocaine Metabolites 150 ng/ml
Gamma Hydroxybutyrate (GHB) 10 mcg/ml
Ketamine 100 ng/ml
LSD 200 pg/ml
Methamphetamine 500 ng/ml (must also contain amphetamine at a concentration equal to or greater than 200 ng/ml)
MDMA, MDA and MDEA 500 ng/ml
Opiates:
- Heroin Metabolite 6-acetylmorphine—10 ng/ml (only if the opiate metabolites are in excess of 2,000 ng/ml)
- Codeine Metabolites 2,000 ng/ml
- Morphine Metabolites 2,000 ng/ml
- Oxycodone 100 ng/ml
- Hydrocodone 300 ng/ml
- Methadone 300 ng/ml
- Hydromorphone 300 ng/ml
- Fentanyl 300 pg/ml
- Propoxyphene 200 ng/ml
- Phencyclidine (PCP) 25 ng/ml

Marijuana

Marijuana Metabolites 35 ng/ml
Synthetic Cannabinoids Any detectable level

I.6 STEROIDS AND PERFORMANCE-ENHANCING DRUGS CONFIRMATORY LABORATORY ANALYSIS LEVELS

All SPEDs (including Human Growth Hormone in its synthetic form and Testosterone in its synthetic form detected through IRMS analysis), except those listed below, at any detectable level.

SPED	Amount
Amphetamines and their analogs	500 ng/ml
Ephedra/Ephedrine	10 mcg/ml
Methylephedrine	10 mcg/ml
Nandrolone	2 ng/ml
Norpseudoephedrine	5 mcg/ml
Phenylpropanolamine (PPA)	25 mcg/ml
Pseudoephedrine	150 mcg/ml

I.7 CREATION OF PLAYER LONGITUDINAL PROFILES

The following protocol will be used to create the Longitudinal Profiles described in Article XXXIII, Section 18 above:

Step 1: Beginning with the 2017-18 Season, the Program’s drug collection company will assign each player a unique personal identification number. A player’s personal identification number will remain the same for all periods of time he is covered by the Program, and will only be used for the purposes of the Longitudinal Profile. Other than to the designated representatives or employees within the drug collection company and the Laboratory, the drug collection company will not disclose the personal identification number that corresponds to the player’s name to any individual other than one representative each of the NBA and the Players Association.
Step 2: The Laboratory (as defined in Article XXXIII, Section 18(a)) will maintain a secure, separate database for each player’s personal identification number that contains his corresponding Testosterone concentration, epitestosterone concentration and Testosterone/Epitestosterone (“T/E”) ratio (referred to collectively as the “Baseline Values”). This database will not contain any identifying information for the players.
Step 3: The Baseline Values will be calculated, pursuant to the Laboratory’s operating standards, by averaging a player’s T/E ratio, Testosterone concentration and Epitestosterone concentration, respectively, from three negative tests conducted under the Program. After a player’s Baseline Values are established, those values will be considered a player’s Longitudinal Profile for the duration of his coverage under the Program. New Baseline Values will be calculated for a player upon the recommendation of the director of the Laboratory.
Step 4: The Laboratory will compare the Baseline Values to the corresponding Specimen Values (as defined in Article XXXIII, Section 18(c)) in subsequent tests identified with a player’s personal identification number in determining whether it will conduct IRMS analysis (as defined in Section 18(a) above) on a urine specimen.